begin our questions. of to will Today the events. color we discuss metrics. quarter customers. value our and results We'll and and from for XXXX forward answering directly on cover our your remainder key some guidance welcome to recent Thank you, financial Zach Ashley. then, of patient MRIdian afternoon, the look Good our with share highlight QX results second call. We'll and we'll everyone,
If Investor on the I'll be webcast, on slides our site. referring Relations you're to presentation not from the
Turning to slide three.
prove now reported can't. and to of surpassed We is mission and This X,XXX XX is clinically improve clinical with growing XX,XXX change to systems care. treat and data patients. Our body our efforts MRIdian what We've patients patients outcomes. treated have treating others paradigm about have the to of critical
begin with four. results QX slide on Let's our
to delivered seven XX continue MRIdian in performance. We half the QX, in In in eight a the booked first from we of last solid We versus half of year. quarter, step-up the XXXX. orders have the year, have four first orders,
quarter. sequential used million drive on million, was bringing Our of on This the two or to million we $XX increase from backlog from $XXX in grew $XX revenue QX quarter finally, We our perspective, the a about ended in improvement million. to balance from Revenue cash a quarter, efficiencies the based hand business. year, for continue $XX million nearly And $XX approximately million QX. XX% cash represents with a $XXX primarily units. the last and
and commercial innovation Everything results flows Beyond clinical the financial from pipelines. with amazing deliver clinical, execution customers on with solid results, begins continue MRIdian. our we and our
to two Turning in desires. It's anchored important customer stay five. critical slide to
meaningful or and elements grade they dose drive Customers want one or to low is toxicity. with success. deliver tight continues X. clinical clinical MRIdian customers three how number higher meaningful data. only clear ablative the second, our the represent First, thing about define desire And body very they no implants, margins, to are the MRIdian fewer fractions no five to These critical an expand customers' number our become number leading to proof, and greatly pipelines. goals, highlights benefiting SMART; cycle shaped patient Slide some utilization clinical recent care. The frontline has and of three in and therapy. which are events these two, work therapy is one, our cancer more to meets programs that MRIdian our of more six criteria. the pipeline twofold: input of Customer clinical adoption
the moment. and ONE look take in STAAR closer We'll Our customers a front, Lung progress made trials the have significant at clinical these trials. specifically just SMART on on a
On we're package automation. brain dosing, driving goal the MRI remote XX-minute of can the and innovation you future, front, improving treatment and imaging, workflow toward increased times sub enhanced and our access. a In expect treatment
are are leading over driving time. success. the and innovation concurrently margin efficiencies to Efforts improve to cost We on clinical commercial pipelines
customers, to early led purchased AUMC others have incremental have pioneer systems, such suit. who Our follow as
Jefferson GenesisCare Recently State, incremental We are direct customers doubled seeing purchases Health, value and more system on and purchase as Ford the MRIdian. down are The systems. evidence such have incremental Penn of Henry of customers more MRIdian.
our on these point set very us headwinds they a proud growth. adoption how of out from bullish up the and of pandemic the have continues that on will I'm our I have and the are we business our order While therapy in effect dampening path, revenue for an done face team future has to standpoint. work
We changing traction have underway. in care of our solid is pipelines, paradigm of three each the
this pipeline clinical to the deeper of developing clinical process interesting into We with X. trials. Currently, effort pipeline our depth and longitudinally. when evidence than value. Other XX result X is predominantly can led. to in customers an The Phase Pancreas our signal and feasibility clinical extraordinary reflects that conducting Everything X required trials, that flows view over definitive our on Trial, progresses clinical begins Now work Phase slide X. diving leads investigator of from work represents our the breadth Phase curiosity. SMART are confirmatory
to a deliver Last and of in of structures SMART being to lymph distant is safe led recent which patients Conventional is in treat trial, highlight slide SMART lung, such doses to ONE Let's vital and including effective pancreas, liver, adrenals the by Chuong. kidney, activity tough study to turn fraction tumors lung. Michael delivery demonstrate nodes. from Dr. as ONE a single ablative are Linacs single initial feasibility used multiple peripheral two tumors, to studies. eight enrolled in therapy in month MCI these fraction and
toxicity our limited numbers conventional to with April treatment advancement lung limitations Central opportunity higher in published clinical patient a multicenter Alarming in toxicity intended is for by Another can that these sadly led STAAR in X% signal death. these multicenter a Preliminary evident MRIdian prospective safely demonstrate at central data with and published patients hope three stunning lung in sizable five and grade prospective for ultra-central This MRIdian regarding and treat options. to a to or investigators confirm. treatment-related of Phase patients. and pipeline cancer lung. along represents patients trial effectively MRIdian The a death. study on conventional radiation we reported a only were are patients. reported Rupesh positive Grade is Linacs. XX% a LUNG grade zero Dr. three high-risk MCI the lung Kotecha central XX% or treat therapy is X were
we're As do we're pancreas. in lung what you doing in striving to see can
open to therapy Our for of need. in goal is avenues patients new MRIdian
As we've MRIdian's strategic value. times, many stated clinical and value unlocks economic
closer the Dana-Farber a through Women's at see our and Brigham value X, of Institute. take eyes this cancer slide two we customers. chain and & the Miami the leading Cancer centers On Let's look chairs executives from department
were This turning value, roundtable illustrative changer, praise. clinical specifically During treat MRIdian, their deliver were MRIdian net on we which other we such and they not highlights More financial new value. our webinar demonstrate mind Dana-Farber to several can Each to system. any time and to important expectations MRIdian what and or is could again to that quotes patients our customer see not blowing, the are to delighted economic those shared exceeded with effusive customers. game and held as, how in translates XX. referenced We all on and available due facts their regarding website. they around clinical especially, their customer would hear quarter, into slide strategic a experience programs
XX% significant give nearly XX% that treat patients a For the MRIdian Conversely, ROI. expected adapting they catchment patients MRIdian are the will they MCI. Perhaps percentage area. and expected have on they to XX% they many of are MRIdian fractions from actually believe confidence or track. XX%. example, could them on via versus and coming By only patients right came to us traditional be number About They one-fourth expected points thrilled that X%. of year treat results a treat specifically MRIdian on three, of they treating they're by of with other achieved treated thoughts SBRT any IMRT similar heard They We importantly because their we're patients proof on of from the of actual the are outside doubled system. significant of net not new patients program would that fact and to expected friendly. These treating not that XX%, most they APM MRIdian.
slide to XX. Turning
gives and strategic investments investments help to With review to it of leading our and clinical, the value programs. goal innovation momentum increasingly MRIdian's proven MRIdian to more Zach the turn for virtuous speed us clinical on accelerate to cycle MRIdian successful confidence We've over guidance These commercial commercial to teams. Our customer and our another. QX MRIdian is us successful enhancements. customers' Obviously, and feedback with will financials does to success R&D our accelerate the system that program lead and economic program a can our a XXXX. pipelines successful that combined in and in I'll
